SecBot SecBot
PRESS-RELEASE ·Filed Jun 8, 2026

LYEL

Lyell Immunopharma, Inc
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The substantial safety improvement and trial amendment to a registrational path are significant catalysts. Monitor for additional Phase 1 data and End-of-Phase 1 FDA meeting in H2 2026, which could de-risk LYL273's regulatory pathway and support a pivotal trial start.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.31
T+0 close · Jun 8, 2026 · via day close
Latest settled
+17.99%
T+60 · $14.53
Vs SPY
+14.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $12.31entry
  2. T+1 · 5mo ago +3.17%α +3.46% · $12.70
  3. T+5 · 5mo ago +10.07%α +7.96% · $13.55
  4. T+20 · 4mo ago +14.05%α +12.42% · $14.04
  5. T+60 · 3mo ago +17.99%α +14.94% · $14.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showing GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%. The trial was amended to a Phase 1/2 design enabling a potential pivotal single-arm Phase 2 trial, with an End-of-Phase 1 FDA meeting and additional clinical data expected in H2 2026.

Key Facts

  • GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% (without prophylaxis, N=9) to 10% (with prophylaxis, N=10).
  • No Grade ≥3 CRS or ICANS observed in patients receiving GI prophylaxis.
  • Maximum tolerated dose has not yet been determined; dose escalation continues.
  • Phase 1 trial amended to Phase 1/2 design (CARABINER) enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.
  • New cohorts added: second-line cohort and combination with radiotherapy; up to 60 patients expected across new cohorts.
  • End-of-Phase 1 FDA meeting and additional Phase 1 clinical data expected in H2 2026.
  • LYL273 has FDA Fast Track designation for mCRC.
  • Previously reported 50% overall response rate across Dose Levels 1 and 2 (data cutoff Oct 28, 2025) in 3L+ mCRC.

Financial Impact

No financial figures disclosed; early-stage clinical data with no revenue or deal value.

Risk Factors

  • Maximum tolerated dose not yet determined; dose escalation could reveal unexpected toxicity.
  • Phase 2 regulatory alignment with FDA is pending and not guaranteed.
  • Small sample size (N=19) limits statistical reliability of safety and efficacy data.
  • Solid tumor CAR-T remains a challenging field with high historical failure rates.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3307886

Track record

21 reports on LYEL

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+1 after the Mar 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026